Compare Abbott Laboratories (ABT) vs Li Auto Inc (LI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Li Auto Inc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Li Auto Inc trades at $12.18 (market cap $11.78B). The key difference: Abbott Laboratories is far larger — about 14.2× Li Auto Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| ABT | LI | |
|---|---|---|
Market Cap | $166.94B | $11.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $31.80 |
52-Week Low | $82.57 | $11.74 |
Enterprise Value | $193.69B | $693.65M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Li Auto (LI) trades at $12.05, near its 52-week low, with a bearish technical outlook. Revenue declined to $112.31B in 2025, and net income fell to $1.12B, reflecting margin pressure. Analyst consensus is mixed with a $14.80 price target, but recent news highlights competitive headwinds and delivery growth of 30,895 vehicles in June 2026.
The stock faces near-term risks from intense EV competition and profitability challenges, but long-term recovery potential exists if L-series execution improves. Investors should weigh low valuation multiples against operational cash flow deficits and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
